Healthcare
Latest Healthcare Analysis
View More
Merck Eyes Incyte for Possible Acquisition
Merck (MRK) is rumored to be pursuing Incyte (INCY), prompting market volatility.
Inside the Market Dominance of the Top 10 Pharma Giants
From innovation to influence. The world's biggest pharma players aren't just leaders. They're industry giants. This infographic shows their...
Evotec Receives Takeover Bid from Halozyme (HALO)
Evotec has received a takeover offer from Halozyme, potentially creating a major player in life sciences. Retail investors should watch for market...
NTRA Stock: Impressive Growth and Rising Profit Margins
Natera's impressive Q3 2024 highlights its strong position in the genetic testing market.
Top Picks
View More
Top Growth Stocks Q2 2022
Growth investing tends to be a medium to long-term investing strategy. Investors looking for growth stocks seek companies that appear to have a...
Top Growth Stocks Q1 2022
Growth investing tends to be a medium to long term investing strategy. Investors looking for growth stocks seek companies that appear to have a...
Top Momentum Stocks Q1 2022
Momentum investing tends to be a short-term investing strategy. Investors looking to buy shares in a stock look for signs of upward momentum and...
Q4 2021 Top Healthcare stocks to consider
Healthcare can be a lucrative investment area, but it's also a challenging sector to invest in. Here are some top health stocks in momentum, growth...
Press Releases
View MoreCardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis
Toronto, ON – February 21, 2024 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences...
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
Designation Based on Pre-clinical Data and Initial Clinical Data from the Company’s MAvERIC-Pilot Phase II Study
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research...
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
Toronto, ON – November 1, 2023 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences...